Trial · NCT07897071
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | DLT events | Up to 28 days | Incidence of dose-limiting toxicity (DLT) events during the dose escalation phase |
| Primary | Incidence and severity of AEs and serious AEs (SAEs) | Up to 3 years | AEs refer to any adverse medical events occurring in participants from the initiation of AXT-1003 and Enzalutamide administration during clinical trials. SAEs denote events involving death, life-threatening conditions, significant disability/incapacity, hospitalization or prolonged hospitalization arising after AXT-1003 and Enzalutamide administration in participants. Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version \[6.0\]). |
| Secondary | rPFS | 3-5 years | Radiographic progression-free survival |
| Secondary | PSA | 3-5 years | Prostate-specific antigen (PSA)-related endpoints: |
| Secondary | Objective response rate (ORR) | 3-5 years | |
| Secondary | Duration of response (DOR) | 3-5 years | |
| Secondary | Pharmacokinetic (PK) Parameters : Maximum Observed Plasma Concentration (Cmax) | Up to 2 years | Multiple dose PK will be calculated as data permits. |
| Secondary | PK Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax) | Up to 2 years | Multiple dose PK will be calculated as data permits. |
| Secondary | PK Parameters: Minimum Observed Plasma Concentration (Cmin) | Up to 2 years | Multiple dose PK will be calculated as data permits. |
| Secondary | PK Parameters: Area Under the Curve (AUC) | Up to 2 years | Multiple dose PK will be calculated as data permits. |
| Secondary | PK Parameters: Apparent Oral Clearance (CL/F) | Up to 2 years | Multiple dose PK will be calculated as data permits. |
| Other | Exploratory Endpoint | Up to 2 years | Change from baseline in blood H3K27me3 levels |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07897071/registered